0A3M Stock Chart & Stats
$103.02
-$1.96(-2.14%)
At close: 4:00 PM EDT
$103.02
-$1.96(-2.14%)
Day’s Range― - ―
52-Week Range$79.51 - $123.69
Previous CloseN/A
Volume819.00
Average Volume (3M)26.64K
Market Cap
$21.82B
Enterprise Value$6.84B
Total Cash (Recent Filing)$9.74B
Total Debt (Recent Filing)$315.97M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 03, 2026EPS Estimate
0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.73
Shares Outstanding251,204,360
10 Day Avg. Volume11,125
30 Day Avg. Volume26,641
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit3.65
Enterprise Value/Ebitda-7.27
Forecast
1Y Price Target
$123.06Price Target Upside19.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-5.43
Revenue Forecast (FY)$1.80B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and substantial equity provide BioNTech with financial flexibility to fund clinical development, absorb volatility, and pursue strategic opportunities. This capital strength is particularly valuable while the company transitions from pandemic-driven revenue toward a broader oncology portfolio.
Promising Oncology PipelineEncouraging pumitamig results in previously treated lung cancer strengthen the case for a differentiated oncology franchise addressing significant unmet need. Responses across disease subtypes and PD-L1 levels support continued development and potential future diversification beyond COVID-related revenue.
Late-stage Development BreadthAdvancing LCD into Phase III, supported by broad clinical experience and a reported favorable safety profile, increases BioNTech’s opportunity to convert its research platform into commercial products. Multiple late-stage programs can diversify future revenue and reduce reliance on one asset.
Bears Say
COVID Revenue DependenceThe sharp decline in vaccine demand exposes BioNTech’s continuing dependence on a product whose market has shifted from pandemic procurement to seasonal use. Lower and less predictable COVID revenue puts greater pressure on oncology programs to generate durable replacement growth.
Sustained Operating LossesHigh gross margins have not offset the cost base required for R&D and SG&A at the current revenue run-rate. Persistent operating losses could reduce returns on equity and require BioNTech to maintain disciplined prioritization while it waits for pipeline programs to mature.
Clinical Efficacy And Safety UncertaintyThe breast cancer ADC result creates meaningful development uncertainty because the efficacy improvement was modest and the safety profile included a higher ILD rate. BioNTech may need additional evidence or strategic changes before this program can support a durable commercial contribution.
BioNTech SE News
0A3M FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest share price was $79.51 and its highest was $123.69 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $21.82B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Nov 03, 2026 which is in 6 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Aug 04, 2026. The company reported -$3.62 earnings per share for the quarter, missing the consensus estimate of -$2.346 by -$1.274.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE does not currently pay dividends.
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is 0.75.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 251,204,360 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$3.62 in its last earnings report, missing expectations of -$2.346. Following the earnings report the stock price went down -1.934%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in GB:0A3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$123.06 (19.45% Upside)
$123.06 (19.45% Upside)
Blogger Sentiment
Bullish
GB:0A3M Sentiment 83%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.79%
12-Months-Change
Fundamentals
Return on Equity
-9.16%
Trailing 12-Months
Asset Growth
-8.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
0A3M Company Deck
0A3M Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.View all GB:0A3M earnings summaries0A3M Stock 12 Month Forecast
Average Price Target
$123.06
▲(19.45% Upside)